# BMS 247550 to Treat Kidney Cancer

> **NCT00030992** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 102 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** BMS-247550
- **DRUG:** Ranitidine
- **DRUG:** Diphenhydramine

## Key facts

- **NCT ID:** NCT00030992
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-02
- **Primary completion:** 2009-01
- **Final completion:** 2012-06
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2012-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00030992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00030992, "BMS 247550 to Treat Kidney Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00030992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*